Clinical Trial Update: The Effects of Rimonabant, on Weight and Metabolic Risk Factors [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the effects of rimonabant on weight and metabolic risk factors; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Obesity
• Schizoaffective Disorder
• Schizophrenia
• Smoking

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: TERMINATED | Results posted: 2015-02-27